Oral antiviral therapy for HBeAg negative chronic hepatitis B: better stop or continue?

Suppr

超能文献

作者信息

Lampertico Pietro

出版信息

Gut. 2015 Apr;64(4):526-8. doi: 10.1136/gutjnl-2014-307596. Epub 2014 Aug 20.

DOI:10.1136/gutjnl-2014-307596

PMID:25143344

Abstract

摘要

相似文献

Oral antiviral therapy for HBeAg negative chronic hepatitis B: better stop or continue?

Gut. 2015 Apr;64(4):526-8. doi: 10.1136/gutjnl-2014-307596. Epub 2014 Aug 20.

Treatment of chronic hepatitis B virus infection - Dutch national guidelines.

Neth J Med. 2008 Jul-Aug;66(7):292-306.

Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy.

Clin Res Hepatol Gastroenterol. 2017 Dec;41(6):635-643. doi: 10.1016/j.clinre.2017.03.004. Epub 2017 Apr 21.

Telbivudine for the treatment of chronic hepatitis B infection.

Health Technol Assess. 2009 Oct;13 Suppl 3:23-30. doi: 10.3310/hta13suppl3/04.

Predictors of hepatitis B e antigen-negative hepatitis in chronic hepatitis B virus-infected patients from childhood to adulthood.

Hepatology. 2016 Jan;63(1):74-82. doi: 10.1002/hep.28222. Epub 2015 Oct 29.

Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?

Clin Mol Hepatol. 2014 Dec;20(4):355-60. doi: 10.3350/cmh.2014.20.4.355. Epub 2014 Dec 24.

Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.

Value Health. 2015 Sep;18(6):800-9. doi: 10.1016/j.jval.2015.05.007. Epub 2015 Jul 27.

Predictive Factors for Sustained Remission after Discontinuation of Antiviral Therapy in Patients with HBeAg-positive Chronic Hepatitis B.

Korean J Gastroenterol. 2016 Jan 25;67(1):28-34. doi: 10.4166/kjg.2016.67.1.28.

Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS).

Antivir Ther. 2008;13(4):555-62.

Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.

Gastroenterology. 2012 Sep;143(3):629-636.e1. doi: 10.1053/j.gastro.2012.05.039. Epub 2012 May 31.

引用本文的文献

Long Term HBsAg Responses to Peg-Interferon Alpha-2b in HBeAg Negative Chronic Hepatitis B Patients Developing Clinical Relapse after Stopping Long-Term Nucleos(t)ide Analogue Therapy.

J Clin Exp Hepatol. 2024 Jan-Feb;14(1):101272. doi: 10.1016/j.jceh.2023.08.008. Epub 2023 Aug 23.

Pathogenetic Mechanisms of Liver-Associated Injuries, Management, and Current Challenges in COVID-19 Patients.

Biomolecules. 2023 Jan 3;13(1):99. doi: 10.3390/biom13010099.

COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management.

Biomed Pharmacother. 2022 Oct;154:113568. doi: 10.1016/j.biopha.2022.113568. Epub 2022 Aug 17.

Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs.

Saudi J Gastroenterol. 2018 Jan-Feb;24(1):30-36. doi: 10.4103/sjg.SJG_228_17.

Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy.

Curr Treat Options Infect Dis. 2016;8:177-193. doi: 10.1007/s40506-016-0080-x. Epub 2016 Jul 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验